EX-99.1 2 a14-4679_1ex99d1.htm EX-99.1

Exhibit 99.1

 

 

 

Lynn Pieper
Investor Relations
+1 (415) 202-5678
Lynn.pieper@westwicke.com

Rebecca Phillips
Public Relations Manager
+1 (408) 716-4773
rphillips@accuray.com

 

Accuray Reports Financial Results for Second Quarter of Fiscal Year 2014

 

Achieves Adjusted EBITDA Profit on Revenue Growth and Margin Expansion

Updates Financial Guidance

 

SUNNYVALE, Calif., January 30, 2014 — Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the second fiscal quarter and six months ended December 31, 2013.

 

Second Quarter Highlights

 

·                  Strong order momentum with gross orders of $80.3 million

·                  Total revenue of $93.6 million increases 20% from the second fiscal quarter 2013

·                  Gross profit margin expands to 40.8%

·                  Achieves adjusted EBITDA of $6.8 million

 

“The second quarter marks our fourth consecutive quarter of net order strength, driven by our improved commercial execution and customer focus.  We are pleased with our strong and improving operational performance during the first half of our fiscal year,” said Joshua H. Levine, president and chief executive officer of Accuray.  “We remain focused on our strategic growth agenda and believe our focus on operational and commercial execution, coupled with fiscal discipline, will continue to create value for all of our stakeholders.”

 

“Our upwardly revised guidance range reflects an anticipation of continued momentum throughout the second half of our fiscal year. We are pleased to report an adjusted EBITDA profit of $6.8 million in the second quarter, as we drive toward achieving sustainable positive cash flow,” said Levine.

 

Financial Highlights

 

Gross product orders totaled $80.3 million for the second quarter, an increase of $40.5 million or 102% over the second quarter of the prior year.  Gross product orders, less cancellations and age-outs, totaled $59.4 million for the second quarter, an increase of $41.5 million or 232% from the second quarter of fiscal 2013.  Ending product backlog of $362 million was approximately 30% higher than backlog at the end of the prior fiscal year second quarter.

 

1



 

Total revenue reached $93.6 million, representing an increase of 20% from the prior year second quarter.  Product revenues totaled $45.1 million and represented an increase of 36% from the prior year second quarter while service revenues totaled $48.5M and represented an increase of 9% over the prior fiscal year second quarter.

 

Total gross profit of $38.2 million represents an increase of 43% from the prior year second quarter.  Total gross profit margin improved to 40.8%, comprised of product gross margin of 44.7% and service gross margin of 37.1%. This compares to total gross margin of 34.2%, product gross margin of 44.0% and service gross margins of 26.9% for the prior fiscal year second quarter.

 

Operating expenses were $38.9 million, compared with $48.9 million in the prior fiscal year second quarter.

 

Net loss was ($5.4) million, or ($0.07) per share for the second quarter of 2014, compared to a net loss of ($29.2) million, or ($0.40) per share for the prior fiscal year second quarter.

 

Adjusted EBITDA for the second quarter of 2014 was a profit of $6.8 million, compared to a loss of ($18.1) million in the prior fiscal year second quarter.

 

Cash, cash equivalents, investments and restricted cash were $162.6 million as of December 31, 2013, a decrease of $1.8 million from September 30, 2013.

 

Six Month Highlights

 

For the six months ended December 31, 2013, total revenue reached $170.3 million, representing an increase of 6% from the comparable period of fiscal year 2013.  Product revenue for the six month period was $74.7 million, representing an increase of 1% while service revenue was $95.6 million, representing an increase of 10% over the comparable prior fiscal year period.

 

Gross profit margin for the six months ended December 31, 2013 was 38.0%, comprised of product gross margin of 41.7% and service gross margin of 35.1%. This compares to total gross margin of 31.3% for the comparable prior fiscal year period.

 

Operating expenses for the six months ended December 31, 2013 of $77.7 million, compared with $93.2 million in the comparable prior fiscal year period.

 

Net loss for the six months ended December 31, 2013 was ($21.0) million, or ($0.28) per share, compared to a net loss of ($53.3) million, or ($0.74) per share for the comparable prior fiscal year period.

 

Adjusted EBITDA for the six months ended December 31, 2013 was a profit of $3.0 million, compared to a loss of ($30.0) million in the comparable prior fiscal year period.

 

2014 Financial Guidance

 

Accuray updated its financial guidance of total revenue for fiscal 2014 to a range of $340 million to $350 million.  This compares to the previous financial guidance of total revenue in the range of $325 million to $345 million which was provided on August 27, 2013 and reaffirmed on November 7, 2013.

 

2



 

Additional Information

 

Additional information including slides of second quarter highlights, which will be discussed during the conference call, is available on the Investor Relations section of the company’s website at www.accuray.com/investors.

 

Earnings Call Open to Investors

 

Accuray will host an investment community conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results and answer questions. Conference call dial-in information is as follows:

 

·                  U.S. callers: (866) 318-8618

·                  International callers: (617) 399-5137

·                  Conference ID Number (U.S. and international): 52092679

 

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website, www.accuray.com. The webcast will be available on the Company’s web site for 14 days following the completion of the call.  In addition, a dial-up replay of the conference call will be available beginning January 30, 2014 at 5:00 p.m. PT/8:00 p.m. ET and ending when Accuray announces its results for the third quarter of fiscal 2014, ending March 31, 2014.  The replay telephone number is 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID: 37382502.

 

Use of Non-GAAP Financial Measures

 

The Company has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation (“adjusted EBITDA”). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company and facilitates a more meaningful comparison of results for current periods with previous operating results.  Additionally, it will assist management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss (the most directly comparable GAAP measure) is provided in the schedule below.

 

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

 

About Accuray

 

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company’s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

 

3



 

Safe Harbor Statement

 

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to continuation of sequential and year over year net bookings or total revenue; momentum in our commercial execution; a trajectory towards profitability; expectation of the continuation of the positive trend in our gross profit margin; continued reductions or maintenance of existing levels of operating expenses. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company’s ability to convert backlog to revenue; the success of its worldwide sales and marketing efforts; the success of the adoption of our CyberKnife and TomoTherapy Systems; the extent of market acceptance for the company’s products and services; the company’s ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K  which was filed on August 29, 2013, and our other filings with the SEC.

 

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

 

###

 

4



 

Accuray Incorporated

Consolidated Statements of Operations

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

Six Months Ended 
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

Net revenue:

 

 

 

 

 

 

 

 

 

Products

 

45,148

 

33,170

 

74,716

 

73,798

 

Services

 

48,486

 

44,609

 

95,559

 

86,729

 

Total net revenue

 

93,634

 

77,779

 

170,275

 

160,527

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

Cost of products

 

24,980

 

18,564

 

43,581

 

42,573

 

Cost of services

 

30,483

 

32,589

 

62,045

 

67,652

 

Total cost of revenue

 

55,463

 

51,153

 

105,626

 

110,225

 

Gross profit

 

38,171

 

26,626

 

64,649

 

50,302

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

13,435

 

17,239

 

26,385

 

35,813

 

Selling and marketing

 

14,262

 

15,761

 

28,716

 

28,650

 

General and administrative

 

11,190

 

15,892

 

22,550

 

28,734

 

Total operating expenses

 

38,887

 

48,892

 

77,651

 

93,197

 

Loss from operations

 

(716

)

(22,266

)

(13,002

)

(42,895

)

Other expense, net

 

(3,775

)

(2,580

)

(6,235

)

(3,284

)

Loss before provision for income taxes

 

(4,491

)

(24,846

)

(19,237

)

(46,179

)

Provision for income taxes

 

950

 

667

 

1,737

 

1,264

 

Loss from continuing operations

 

(5,441

)

(25,513

)

(20,974

)

(47,443

)

Loss from discontinued operations attributable to stockholders

 

 

(3,658

)

 

(5,858

)

Net loss attributable to stockholders

 

$

(5,441

)

$

(29,171

)

$

(20,974

)

$

(53,301

)

 

 

 

 

 

 

 

 

 

 

Loss per share attributable to stockholders

 

 

 

 

 

 

 

 

 

Basic and diluted - continuing operations

 

$

(0.07

)

$

(0.35

)

$

(0.28

)

$

(0.65

)

Basic and diluted - discontinued operations

 

$

 

$

(0.05

)

$

 

$

(0.09

)

Basic and diluted - net loss

 

$

(0.07

)

$

(0.40

)

$

(0.28

)

$

(0.74

)

Weighted average common shares used in computing loss per share

 

 

 

 

 

 

 

 

 

Basic and diluted

 

75,280

 

72,870

 

74,990

 

72,433

 

 

5



 

Accuray Incorporated

Consolidated Balance Sheets

(in thousands)

(Unaudited)

 

 

 

December 31,

 

June 30,

 

 

 

2013

 

2013

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash, cash equivalents and investments

 

$

159,649

 

$

174,397

 

Restricted cash

 

2,956

 

2,728

 

Accounts receivable, net of allowance for doubtful accounts

 

73,777

 

55,458

 

Inventories

 

88,153

 

81,592

 

Prepaid expenses and other current assets

 

13,304

 

12,595

 

Deferred cost of revenue

 

12,522

 

9,165

 

Total current assets

 

350,361

 

335,935

 

Property and equipment, net

 

35,569

 

34,733

 

Goodwill

 

58,163

 

59,368

 

Intangible assets, net

 

27,494

 

31,896

 

Deferred cost of revenue

 

2,309

 

2,149

 

Other assets

 

11,307

 

11,848

 

Total assets

 

$

485,203

 

$

475,929

 

Liabilities and equity

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable

 

$

15,111

 

$

15,920

 

Accrued compensation

 

17,713

 

12,461

 

Other accrued liabilities

 

23,583

 

22,893

 

Customer advances

 

21,239

 

17,692

 

Deferred revenue

 

96,527

 

86,893

 

Total current liabilities

 

174,173

 

155,859

 

Long-term liabilities:

 

 

 

 

 

Long-term other liabilities

 

5,603

 

5,382

 

Deferred revenue

 

9,168

 

9,085

 

Long-term debt

 

201,082

 

198,768

 

Total liabilities

 

390,026

 

369,094

 

Equity:

 

 

 

 

 

Common stock and additional paid-in capital

 

433,333

 

424,599

 

Accumulated other comprehensive income

 

2,464

 

1,882

 

Accumulated deficit

 

(340,620

)

(319,646

)

Total equity

 

95,177

 

106,835

 

Total liabilities and equity

 

$

485,203

 

$

475,929

 

 

6



 

Accuray Incorporated

Reconciliation of GAAP net loss to Adjusted Earnings Before Interest, Taxes, Depreciation,

Amortization and Stock-Based Compensation (Adjusted EBITDA)

(In thousands)

(Unaudited)

 

 

 

Three Months Ended
December 31,

 

Six Months Ended 
December 31,

 

 

 

2013

 

2012

 

2013

 

2012

 

GAAP net loss

 

$

(5,441

)

$

(29,171

)

$

(20,974

)

$

(53,301

)

Amortization of intangibles (a) 

 

2,201

 

2,184

 

4,403

 

6,013

 

Depreciation (b) 

 

2,927

 

3,909

 

6,173

 

7,907

 

Stock-based compensation (c) 

 

2,803

 

2,296

 

4,983

 

4,051

 

Interest expense, net (d) 

 

3,341

 

2,062

 

6,647

 

4,095

 

Provision for income taxes

 

950

 

667

 

1,737

 

1,264

 

Adjusted EBITDA

 

$

6,781

 

$

(18,053

)

$

2,969

 

$

(29,971

)

 


(a) consists of amortization of intangibles - developed technology, distributor licenses and backlog

(b) consists of depreciation, primarily on property and equipment

(c) consists of stock-based compensation in accordance with ASC 718

(d) consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes

 

7